Advanced Medical Isotope Corporation (trading symbol QB:ADMD)
1021 N. Kellogg St. Kennewick, Washington 99336 US
T: 509.736.4000 F: 509.736.4007 E: info@isotopeworld.com

Tags

Latest News

Advanced Medical Isotope CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission

(Tue, 14, Feb 2017) >> read more

 

Advanced Medical Isotope CEO Issues Letter to Shareholders Issues Full Status Update, Planned FDA Submission Pathway and Business Plan for 2017 and Beyond

(Wed, 11, Jan 2017) >> read more

 

Advanced Medical Isotope announced today that Dr. Michael Korenko, Ph. D., who formerly served as an advisor to the Board, was named as AMI's interim President and Chief Executive Officer, replacing James Katzaroff.

(Tue, 20, Dec 2016) >> read more

 

Advanced Medical Isotope announced today that it has been awarded in the Superior Court of the State of Washington in and for Benton County, a total judgment of $527,875.74 USD. 
(Fri, 2, Dec 2016) >> read more

 

 Click here for more news and updates

Social Media


Investor Relations.

Advanced Medical Isotope Corporation (Trading symbol QB: ADMD) is committed to providing shareholders with complete, up-to-the-minute information about the company. Within this section of our website, you'll find stock information, Board of Directors and other corporate information.

 

Thank you for your past and continued support investing in Advanced Medical Isotope Corporation, and for supporting our mission of developing technologies that will improve human life.

Advanced Medical Isotope Corporation (AMIC) is a late stage development company engaged primarily in the development of brachytherapy devices for therapeutic applications. AMIC's focus is on transitioning to full operations upon receipt of expected FDA clearance for its patented brachytherapy cancer product, Yttrium-90 RadioGel™.

– Mike Korenko - CEO